CliffBio
small molecule

PANTOPRAZOLE SODIUM

PANTOPRAZOLE SODIUM

Loss of exclusivity—loss of exclusivity
CompanyFresenius Kabi →See this company's full patent-cliff portfolio

Drug detail

Brand namePANTOPRAZOLE SODIUM
Active ingredientPANTOPRAZOLE SODIUM
StrengthEQ 40MG BASE/VIAL
Dosage formPOWDER
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalAugust 2024
Marketing statusRX

More from Fresenius Kabi

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.